Bioline Rx reported $7.91M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Arca Biopharma USD 49.52M 2.58M Mar/2026
Bio Path 13.65M 3.37M Sep/2022
Bioline Rx USD 7.91M 725K Sep/2025
Capricor Therapeutics USD 105.42M 182.42M Mar/2026